(FILE 'HOME' ENTERED AT 14:49:05 ON 10 JAN 2003)

FILE 'MEDLINE, CANCERLIT, EMBASE, BIOTECHDS, CAPLUS' ENTERED AT 14:49:17
ON 10 JAN 2003

L1	129	S	POLYEPITOPE# OR MULITPLE EPITOPE#
L2	2533845	S	DNA OR CONSTRUCT OR VECTOR OR PLASMID OR NUCLEIC
L3	94	S	L1 AND L2
L4	37		DUP REM L3 (57 DUPLICATES REMOVED)
L5	29499	S	HPV
L6	102145	S	DNA VACCINE OR IMMUNOGEN?
L7	481	S	L6 AND L5
L8	87	S	L7 AND DNA VACCINE
L9	0	S	L8 AND L1
L10	43		DUP REM L8 (44 DUPLICATES REMOVED)

L10 ANSWER 7 OF 43 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 2002367187 EMBASE
TI Chimeric human papilloma virus-simian/human immunodeficiency virus virus-like-particle vaccines: **Immunogenicity** and protective efficacy in macaques.
AU Dale C.J.; Liu X.S.; De Rose R.; Purcell D.F.J.; Anderson J.; Xu Y.; Leggatt G.R.; Frazer I.H.; Kent S.J.
CS S.J. Kent, Department of Microbiology, University of Melbourne, Parkville, Vic. 3010, Australia. skent@unimelb.edu.au
SO Virology, (2002) 301/1 (176-187).
Refs: 47
ISSN: 0042-6822 CODEN: VIRLAX
CY United States
DT Journal; Article
FS 004 Microbiology
037 Drug Literature Index
LA English
SL English
AB Vaccines to efficiently block or limit sexual transmission of both HIV and human papilloma virus (**HPV**) are urgently needed. Chimeric virus-like-particle (VLP) vaccines consisting of both multimerized **HPV** L1 proteins and fragments of SIV gag p27, HIV-1 tat, and HIV-1 rev proteins (**HPV**-SHIV VLPs) were constructed and administered to macaques both systemically and mucosally. An additional group of macaques first received a priming vaccination with DNA vaccines expressing the same SIV and HIV-1 antigens prior to chimeric **HPV**-SHIV VLP boosting vaccinations. Although **HPV** L1 antibodies were induced in all immunized macaques, weak antibody or T cell responses to the chimeric SHIV antigens were detected only in animals receiving the DNA prime/**HPV**-SHIV VLP boost vaccine regimen. Significant but partial protection from a virulent mucosal SHIV challenge was also detected only in the prime/boosted macaques and not in animals receiving the **HPV**-SHIV VLP vaccines alone, with three of five prime/boosted animals retaining some CD4+ T cells following challenge. Thus, although some **immunogenicity** and partial protection was observed in non-human primates receiving both DNA and chimeric **HPV** -SHIV VLP vaccines, significant improvements in vaccine design are required before we can confidently proceed with this approach to clinical trials. .COPYRGT. 2002 Elsevier Science (USA).

L10 ANSWER 33 OF 43 MEDLINE DUPLICATE 13
AN 2000484707 MEDLINE
DN 20389723 PubMed ID: 10930677
TI Induction of an **HPV** 6bL1-specific mucosal IgA response by DNA immunization.
AU Schreckenberger C; Sethupathi P; Kanjanahaluethai A; Muller M; Zhou J; Gissmann L; Qiao L
CS Department of Microbiology and Immunology, Stritch School of Medicine, Loyola University Medical Center, Maywood, IL, USA.
SO VACCINE, (2000 Sep 15) 19 (2-3) 227-33.
Journal code: 8406899. ISSN: 0264-410X.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200010
ED Entered STN: 20001019
Last Updated on STN: 20001019
Entered Medline: 20001012
AB Human papillomavirus (**HPV**) plays a crucial role in the development of human anogenital dysplasia. To prevent infection, it is important to induce an **HPV**-specific mucosal immune response. We investigated whether DNA vaccination would induce an intravaginal mucosal antibody response against **HPV** 6bL1. New Zealand White rabbits were immunized with an **HPV** 6bL1 ***DNA*** **vaccine** by one of the three routes: muscular, vaginal, or rectal. We found that vaginal immunization of rabbits with **HPV** 6bL1 DNA induced 6bL1 virus-like particle-specific lgA antibodies in vaginal secretions. They were detectable until at least 14 weeks after the first immunization. The antibodies also showed neutralizing activity in a hemagglutination inhibition assay. No mucosal immune response was detected in vaginal secretions of rabbits immunized intramuscularly or intrarectally. Our data suggest that vaginal immunization with **HPV** 6bL1 DNA induces long-lasting IgA responses with neutralizing activity in vaginal secretions of rabbits.

WEST

Freeform Search

Database: US Patents Full-Text Database; US Pre-Grant Publication Full-Text Database; JPO Abstracts Database; EPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Term: L4 with l1

Display: 10 **Documents in Display Format:** - **Starting with Number** 1

Generate: ○ Hit List ◉ Hit Count ○ Side by Side ○ Image

Search | Clear | Help | Logout | Interrupt

Main Menu | Show S Numbers | Edit S Numbers | Preferences | Cases

Search History

DATE: Friday, January 10, 2003 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ			
L5	L4 with l1	4	L5
L4	HPV	2222	L4
L3	l2 with l1	5	L3
L2	dna vaccine or plasmid or nucleic acid construct or dna construct or vector	246183	L2
L1	polyepito$ or mulitiple epitope	509	L1

END OF SEARCH HISTORY